telmisartan has been researched along with pioglitazone in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (7.69) | 29.6817 |
| 2010's | 30 (76.92) | 24.3611 |
| 2020's | 6 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Goebel, M; Gust, R; Kintscher, U; Markt, P; Staels, B; Unger, T; Wolber, G | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bigge, CF; Casimiro-Garcia, A; Chen, J; Davis, JA; Dudley, DA; Edmunds, JJ; Ellis, T; Esmaeil, N; Filzen, GF; Flynn, D; Geyer, A; Heemstra, RJ; Jalaie, M; Ohren, JF; Ostroski, R; Schaum, RP; Stoner, C | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Bigge, CF; Casimiro-Garcia, A; Chen, J; Ciske, FA; Davis, JA; Ellis, T; Esmaeil, N; Flynn, D; Han, S; Heemstra, RJ; Jalaie, M; Ohren, JF; Powell, NA | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Gust, R; Kaserer, T; Obermoser, V; Schuster, D; Weninger, A | 1 |
| Gust, R; Kintscher, U; Murgueitio, MS; Obermoser, V; Urban, ME; Wolber, G | 1 |
| Czifersky, M; Gust, R; Kintscher, U; Lipova, M; Mauersberger, R; Obermoser, V; Schuster, D; Siegl, M | 1 |
| Chin, J; Choi, H; Choung, W; Hong, E; Jang, SM; Jang, TH; Jung, HJ; Jung, K; Kim, KH; Kim, SH; Kim, WS; Lee, BR; Lee, G; Lim, JS; Myung, J; Nam, EH; Park, M; Yang, D | 1 |
| Gust, R; Obexer, P; Salcher, S; Schoepf, AM | 3 |
| Clemenz, M; Gineste, R; Helleboid, S; Hennuyer, N; Janke, J; Kintscher, U; Ruiz, P; Schupp, M; Staels, B; Unger, T; Witt, H | 1 |
| Boschmann, M; Engeli, S; Gorzelniak, K; Janke, J; Jordan, J; Luft, FC; Nystrom, FH; Sauma, L; Schupp, M; Sharma, AM | 1 |
| Fujita, K; Inamori, M; Iwasaki, T; Kirikoshi, H; Maeyama, S; Mawatari, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Terauchi, Y; Wada, K; Yoneda, M | 1 |
| Aubert, G; Burnier, M; Dulloo, A; Mazzolai, L; Perregaux, C; Pralong, F; Zanchi, A | 1 |
| Kagota, S; Kunitomo, M; Nakamura, K; Nejime, N; Shinozuka, K; Tada, Y | 1 |
| Bähr, IN; Kappert, K; Kintscher, U; Krüger, J; Parhofer, KG; Schimkus, J; Scholze, J; Stark, RG; Tretter, P; Unger, T | 1 |
| Hirata, Y; Hishikari, K; Isobe, M; Masumura, M; Nagai, R; Nagashima, A; Ogawa, M; Shimizu, T; Suzuki, J; Takayama, K; Watanabe, R | 1 |
| Tawfik, MK | 1 |
| Atkinson, J; Capdeville-Atkinson, C; Dupuis, F; Foulquier, S; Gatè, KM; Lartaud, I; Leroy, P; Liminana, P; Perrin-Sarrado, C | 1 |
| To, KK; Tomlinson, B | 1 |
| Li, LY; Luo, R; Sun, LT; Tian, FS; Xiong, HL; Zhao, ZQ; Zheng, XL | 1 |
| Gu, Y; Körbel, C; Laschke, MW; Menger, MD; Nenicu, A | 1 |
| Furumura, M; Hashimoto, T; Karashima, T; Numata, S; Ohyama, B; Tanida, N; Teye, K; Yan, Y | 1 |
| Cheng, H; Jiang, L; Shang, Y; Shi, TL; Wang, L | 1 |
| Ali, EF; Mahdi, EA; Mahmoud, FA; Mostafa-Hedeab, G; Shahataa, MG | 1 |
| Chatterjee, B; Das, A; Das, SK; Ibrahim, F; Kifayatullah, M; Mahmood, S; Mandal, UK; Sengupta, P | 1 |
| Chatterjee, B; Pal, TK; Sengupta, P | 1 |
| Alaiyed, S; Elkahloun, AG; Rodriguez, Y; Saavedra, JM; Wenzel, E | 1 |
| Lee, TH; Li, YR; Lin, YS; Liu, CH; Sung, PS; Wei, YC | 1 |
| Izutsu, KI; Kataoka, M; Masada, T; Matsui, K; Minami, K; Takagi, T; Yamashita, S | 1 |
| Ahmed, MAE; El Sayed, NS; El-Sahar, AE; Mansour, RM | 1 |
2 review(s) available for telmisartan and pioglitazone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis.
Topics: Alzheimer Disease; Benzimidazoles; Benzoates; Humans; Pioglitazone; PPAR gamma; Rosiglitazone; Telmisartan; Thiazolidinediones | 2016 |
1 trial(s) available for telmisartan and pioglitazone
| Article | Year |
|---|---|
High-dose treatment with telmisartan induces monocytic peroxisome proliferator-activated receptor-γ target genes in patients with the metabolic syndrome.
Topics: Adult; Angiotensin II Type 2 Receptor Blockers; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Benzimidazoles; Benzoates; Blood Pressure; CD36 Antigens; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Interleukin-6; Male; Metabolic Syndrome; Middle Aged; Monocytes; Pioglitazone; PPAR gamma; Receptors, Cell Surface; Telmisartan; Thiazolidinediones | 2011 |
36 other study(ies) available for telmisartan and pioglitazone
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Characterization of new PPARgamma agonists: benzimidazole derivatives-importance of positions 5 and 6, and computational studies on the binding mode.
Topics: 3T3-L1 Cells; Animals; Benzimidazoles; Benzoates; Cell Differentiation; Chlorocebus aethiops; COS Cells; Mice; Models, Molecular; PPAR gamma; Protein Binding; Telmisartan | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biological Availability; Blood Glucose; Crystallography, X-Ray; Drug Partial Agonism; Humans; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Male; Models, Molecular; PPAR gamma; Pyridines; Radioligand Assay; Rats; Rats, Inbred SHR; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation; Triglycerides | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Crystallography, X-Ray; Humans; Imidazoles; Inhibitory Concentration 50; Models, Molecular; Molecular Conformation; PPAR gamma; Protein Binding; Pyridines; Pyridones; Receptor, Angiotensin, Type 1; Telmisartan | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Evaluation of selected 3D virtual screening tools for the prospective identification of peroxisome proliferator-activated receptor (PPAR) γ partial agonists.
Topics: Animals; Chlorocebus aethiops; COS Cells; Drug Evaluation, Preclinical; Drug Partial Agonism; Molecular Docking Simulation; PPAR gamma; Protein Conformation; User-Computer Interface | 2016 |
New telmisartan-derived PPARγ agonists: Impact of the 3D-binding mode on the pharmacological profile.
Topics: 3T3-L1 Cells; Animals; Benzimidazoles; Benzoates; Cell Differentiation; Chlorocebus aethiops; COS Cells; Drug Design; Mice; Molecular Docking Simulation; PPAR gamma; Protein Binding; Protein Conformation; Structure-Activity Relationship; Telmisartan; Transcriptional Activation | 2016 |
Importance of 5/6-aryl substitution on the pharmacological profile of 4'-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid derived PPARγ agonists.
Topics: Benzimidazoles; Benzoates; Humans; Models, Molecular; Nuclear Receptor Co-Repressor 1; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; Protein Binding; Structure-Activity Relationship; Telmisartan | 2017 |
Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.
Topics: 3T3-L1 Cells; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mice; Oxadiazoles; PPAR gamma; Proof of Concept Study; Pyrimidines; Pyrimidinones; Structure-Activity Relationship | 2019 |
Overcoming imatinib resistance in chronic myelogenous leukemia cells using non-cytotoxic cell death modulators.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Cells, Cultured; Chlorocebus aethiops; COS Cells; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
Topics: Animals; Cell Death; Cell Proliferation; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; PPAR gamma; Structure-Activity Relationship; Telmisartan | 2020 |
Tackling resistance in chronic myeloid leukemia: Novel cell death modulators with improved efficacy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Drug Design; Drug Resistance, Neoplasm; Gene Expression Regulation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nitriles; Phosphorylation; PPAR gamma; STAT5 Transcription Factor; Telmisartan; Transcriptional Activation; Tumor Suppressor Proteins | 2021 |
Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
Topics: 3T3 Cells; Acrylates; Adipocytes; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Biphenyl Compounds; Cell Differentiation; Chlorocebus aethiops; COS Cells; Gene Expression Regulation; Imidazoles; Irbesartan; Mice; Pioglitazone; PPAR gamma; Protein Conformation; Telmisartan; Tetrazoles; Thiazolidinediones; Thiophenes | 2005 |
Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation.
Topics: Adipogenesis; Adiponectin; Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Humans; Irbesartan; Lipoprotein Lipase; Losartan; Luciferases; Male; Pioglitazone; PPAR gamma; Receptor, Angiotensin, Type 1; RNA, Messenger; Telmisartan; Tetrazoles; Thiazolidinediones | 2006 |
Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats.
Topics: Actins; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Biomarkers; Blotting, Western; Collagen Type I; Disease Models, Animal; Disease Progression; Fatty Liver; Hypoglycemic Agents; Immunohistochemistry; Male; Pioglitazone; PPAR gamma; Rats; Rats, Inbred F344; Spectrophotometry; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome; Valine; Valsartan | 2007 |
Neuroendocrine characterization and anorexigenic effects of telmisartan in diet- and glitazone-induced weight gain.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anorexia; Benzimidazoles; Benzoates; Blood Glucose; Body Composition; Body Weight; Diet; Drinking Behavior; Feeding Behavior; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurosecretory Systems; Pioglitazone; Receptor, Angiotensin, Type 1; Reverse Transcriptase Polymerase Chain Reaction; Telmisartan; Thiazolidinediones; Weight Gain | 2010 |
Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood; Blood Glucose; Blood Pressure; Cholesterol; Crosses, Genetic; Guanylate Cyclase; Hypoglycemic Agents; Insulin; Male; Mesenteric Arteries; Metabolic Syndrome; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Nitroprusside; Phenylephrine; Pioglitazone; Rats; Rats, Inbred SHR; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Telmisartan; Thiazolidinediones; Triglycerides; Tyrosine; Vasoconstriction; Vasodilation | 2011 |
Different roles of PPAR-γ activity on physiological and pathological alteration after myocardial ischemia.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channel Blockers; Cells, Cultured; Disease Models, Animal; Drug Partial Agonism; Fibrosis; Hypertrophy, Left Ventricular; Male; Matrix Metalloproteinase 2; Myocardial Infarction; Myocardium; Pioglitazone; PPAR gamma; Rats; Rats, Sprague-Dawley; Stroke Volume; Telmisartan; Thiazolidinediones; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2012 |
Renoprotective activity of telmisartan versus pioglitazone on ischemia/reperfusion induced renal damage in diabetic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Catalase; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glutathione; Hypoglycemic Agents; Inflammation Mediators; Kidney; Lipid Peroxidation; Lipid Peroxides; Oxidative Stress; Pioglitazone; Rats; Reperfusion Injury; Superoxide Dismutase; Telmisartan; Thiazolidinediones; Time Factors; Tumor Necrosis Factor-alpha | 2012 |
Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR.
Topics: Angiotensin Receptor Antagonists; Animals; Arterioles; Benzimidazoles; Benzoates; Biphenyl Compounds; Brain; Cerebrovascular Circulation; Hypertension; Male; Microcirculation; Muscle, Smooth; Nitric Oxide Synthase Type III; Pia Mater; Pioglitazone; PPAR gamma; Rats; Rats, Inbred SHR; Receptor, Angiotensin, Type 1; RNA, Messenger; Telmisartan; Tetrazoles; Thiazolidinediones | 2012 |
Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Benzoates; Biological Transport; Breast Neoplasms; Chlorophyll; Drug Resistance, Neoplasm; Endocytosis; Female; HEK293 Cells; Humans; Kinetics; MCF-7 Cells; Neoplasm Proteins; Phosphatidylinositol 3-Kinase; Pioglitazone; PPAR gamma; Protein Transport; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; Rosiglitazone; Signal Transduction; Telmisartan; Thiazolidinediones; Transfection; Up-Regulation | 2013 |
Angiotensin II receptor blocker telmisartan prevents new-onset diabetes in pre-diabetes OLETF rats on a high-fat diet: evidence of anti-diabetes action.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Body Weight; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Gene Expression; Hypoglycemic Agents; Inflammation; Insulin Resistance; Male; Metformin; Pioglitazone; Rats; Rats, Inbred OLETF; Telmisartan; Thiazolidinediones | 2013 |
Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Down-Regulation; Endometriosis; Female; Gene Expression Profiling; Mice; Neovascularization, Pathologic; Peritoneal Diseases; Pioglitazone; PPAR gamma; Telmisartan; Thiazolidinediones; Up-Regulation | 2014 |
Various peroxisome proliferator-activated receptor (PPAR)-γ agonists differently induce differentiation of cultured human keratinocytes.
Topics: Anti-Inflammatory Agents; Benzimidazoles; Benzoates; Cell Differentiation; Cells, Cultured; Chromans; Filaggrin Proteins; Gene Expression Regulation; Humans; Intermediate Filament Proteins; Keratinocytes; Membrane Proteins; Microscopy, Fluorescence; Pioglitazone; PPAR gamma; RNA, Messenger; Rosiglitazone; Skin; Telmisartan; Thiazolidinediones; Troglitazone | 2015 |
Effects of telmisartan and pioglitazone on high fructose induced metabolic syndrome in rats.
Topics: Animals; Benzimidazoles; Benzoates; Blood Glucose; Drug Therapy, Combination; Fructose; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Pioglitazone; Rats; Rats, Sprague-Dawley; Telmisartan; Thiazolidinediones; Treatment Outcome | 2016 |
Safety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Dose-Response Relationship, Drug; Female; Hypoglycemic Agents; Male; Pioglitazone; Polypharmacy; Rats, Wistar; Risk Assessment; Telmisartan; Thiazolidinediones; Time Factors; Toxicity Tests, Subchronic | 2016 |
Assessment of preclinical pharmacokinetics and acute toxicity of pioglitazone and telmisartan combination.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypertension; Hypoglycemic Agents; Insulin; Male; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Telmisartan; Thiazolidinediones | 2017 |
Telmisartan Protects a Microglia Cell Line from LPS Injury Beyond AT1 Receptor Blockade or PPARγ Activation.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Brain Diseases; Cell Line; Down-Regulation; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Lipopolysaccharides; Mice, Inbred C57BL; Microglia; Neuroprotective Agents; Pioglitazone; PPAR gamma; Telmisartan; Up-Regulation | 2019 |
Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study.
Topics: Aged; Antihypertensive Agents; Brain Ischemia; Databases, Factual; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Taiwan; Telmisartan; Time Factors; Treatment Outcome | 2020 |
In Vitro Sensitivity Analysis of the Gastrointestinal Dissolution Profile of Weakly Basic Drugs in the Stomach-to-Intestine Fluid Changing System: Explanation for Variable Plasma Exposure after Oral Administration.
Topics: Administration, Oral; Biological Variation, Population; Body Fluids; Chemistry, Pharmaceutical; Computer Simulation; Gastric Mucosa; Gastrointestinal Absorption; Humans; Hydrogen-Ion Concentration; Intestinal Mucosa; Permeability; Pioglitazone; Solubility; Tablets; Taurocholic Acid; Telmisartan; Terbinafine | 2021 |
Addressing Peroxisome Proliferator-Activated Receptor-gamma in 3-Nitropropionic Acid-Induced Striatal Neurotoxicity in Rats.
Topics: Animals; Glycogen Synthase Kinase 3 beta; Nitro Compounds; Pioglitazone; PPAR gamma; Propionates; Rats; Telmisartan | 2022 |